Fig. 2

Patient responses on study. a Days on study for each evaluable patient segregated into concurrent treatments (Cohorts 1 and 2-dose escalation and Schedule A) and the alternating weekly schedule (Schedule B). b Days on study based on tumour type in the concurrent treatments. c Kaplan-Meir curve evaluating progression free survival in all evaluable patients. d Waterfall plot of the number of days on study of evaluable patients in this study